Post Covid-19, is Pharma and MedTech commercial model obsolete ?
The Covid-19 outbreak, with countless of cases and half a million deaths to date, has brought a massive impact to patients, families, and health professionals.
It has also profoundly transformed Pharma, Biotech and MedTech companies, both from an innovation and commercialization perspective.
But, as restrictions are progressively lifted in Asia and Europe, will we all go back to business as usual, once the wave has passed, or is the industry going through a massive, irreversible, and accelerated transformation ?
Covid outbreak has accelerated Pharma and MedTech digital transformation. Hybrid commercial model, based on integrated omni-channel, is the critical next step.